Get the Stockscreener App
9.375
3.05%
-0.295
After Hours:
9.38
0.005
+0.05%
Alpha Cognition Inc stock is traded at $9.375, with a volume of 79,338.
It is down -3.05% in the last 24 hours and up +34.70% over the past month.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
See More
Previous Close:
$9.67
Open:
$9.69
24h Volume:
79,338
Relative Volume:
0.75
Market Cap:
$149.46M
Revenue:
-
Net Income/Loss:
$-14.72M
P/E Ratio:
-3.3127
EPS:
-2.83
Net Cash Flow:
$-7.41M
1W Performance:
+0.48%
1M Performance:
+34.70%
6M Performance:
+65.64%
1Y Performance:
+0.00%
1-Day Range:
$9.05
$10.10
1-Week Range:
$8.845
$10.35
52-Week Range:
$3.75
$11.40
Alpha Cognition Inc Stock (ACOG) Company Profile
Name
Alpha Cognition Inc
Sector
Industry
Phone
(858) 344-4375
Address
1200-750 W PENDER ST, VANCOUVER
Compare ACOG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACOG
Alpha Cognition Inc
|
9.375 | 149.46M | 0 | -14.72M | -7.41M | -2.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Alpha Cognition Inc Stock (ACOG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-25 | Initiated | H.C. Wainwright | Buy |
Alpha Cognition Inc Stock (ACOG) Latest News
Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory - Insider Monkey
Alpha Cognition Inc. Common Stock (NASDAQ:ACOG) Q1 2025 Earnings Call Transcript - MSN
Alpha Cognition: Launching A Differentiated Drug Into A Large Alzheimer's Market Opportunity - Seeking Alpha
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025 - TradingView
Alpha Cognition (NASDAQ:ACOG) Earns “Buy” Rating from HC Wainwright - Defense World
We Think Alpha Cognition (NASDAQ:ACOG) Can Easily Afford To Drive Business Growth - Yahoo Finance
Alpha Cognition Inc. Reports Strong Q1 2025 Performance - TipRanks
Alpha Cognition’s Earnings Call Highlights Success and Growth - TipRanks
Alpha Cognition’s Strong Financial Performance and Promising Alzheimer’s Treatment Drive Buy Rating - TipRanks
Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Alpha Cognition Q1 2025 Earnings Call Transcript - MarketBeat
ALPHA COGNITION Earnings Results: $ACOG Reports Quarterly Earnings - Nasdaq
Alpha Cognition Inc. SEC 10-Q Report - TradingView
Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview - BioSpace
Alpha Cognition (ACOG) Expected to Announce Earnings on Tuesday - Defense World
Alpha Cognition, Inc.’s (NASDAQ:ACOG) Lock-Up Period To Expire on May 12th - Defense World
Will Alpha Cognition's Recently Launched Alzheimer's Drug Be A Commercial Success? - RTTNews
Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview - BioSpace
Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference - The Kingston Whig Standard
Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer’s Association International Conference - Yahoo Finance
(Benzgalantamine) Clinical Data at 2025 Alzheimer’s Association International Conference - Business Wire
Alpha Cognition Inc. Reports Strong 2024 Financials - TipRanks
Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens - BioSpace
Alpha Cognition announces board changes - Investing.com
Alpha Cognition announces board changes By Investing.com - Investing.com Canada
Alpha Cognition Appoints Robert Wills To Board - citybiz
Alpha Cognition Earnings Call: Positive Outlook Amid Growth - TipRanks
Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China - The Globe and Mail
Alpha Cognition stock hits 52-week low at $4.65 amid downturn - Investing.com Canada
HC Wainwright Expects Stronger Earnings for Alpha Cognition - Defense World
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024 - TradingView
Alpha Cognition (NASDAQ:ACOG) Given Buy Rating at HC Wainwright - Defense World
Alpha Cognition Inc. (ACOG) reports earnings - Quartz
Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview - Business Wire
Earnings Scheduled For March 31, 2025 - Benzinga
Comparing Alpha Cognition (ACOG) and The Competition - Defense World
Alpha Cognition (NASDAQ:ACOG) Upgraded at Raymond James - Defense World
Contrasting Alpha Cognition (NASDAQ:ACOG) & Cognition Therapeutics (NASDAQ:CGTX) - Defense World
Alpha Cognition (ACOG) Projected to Release Quarterly Earnings on Wednesday - Defense World
Alpha Cognition Inc Stock (ACOG) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):